.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AD02_Tacrolimus.Tacrolimus .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AD02_Tacrolimus.Tacrolimus| name: | Tacrolimus |
| ATC code: | L04AD02 | route: | oral |
| n-compartments | 2 |
Tacrolimus is an immunosuppressant macrolide used primarily to prevent organ transplant rejection and to treat certain autoimmune diseases. It acts by inhibiting calcineurin, thus suppressing T-lymphocyte activation. It is approved and remains widely used in clinical practice, particularly for kidney, liver, and heart transplant recipients.
Pharmacokinetic model parameters reported for adult kidney transplant recipients following oral administration in the early post-transplant period, population containing both sexes.
Martial, LC, et al., & Moes, DJAR (2021). Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. British journal of clinical pharmacology 87(11) 4262–4272. DOI:10.1111/bcp.14842 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33786892
Teng, F, et al., & Wei, H (2022). Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Biopharmaceutics & drug disposition 43(2) 76–85. DOI:10.1002/bdd.2311 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35220592
Kamp, J, et al., & Moes, DJAR (2023). Meltdose Tacrolimus Population Pharmacokinetics and Limited Sampling Strategy Evaluation in Elderly Kidney Transplant Recipients. Pharmaceutics 16(1) –. DOI:10.3390/pharmaceutics16010017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38276495